Related Experiment Video
Updated: Dec 21, 2025
06:07
Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
Published on: August 5, 2022
2.9K
Structure-Guided Identification of DNMT3B Inhibitors
Ana S Newton1, John C Faver1, Goran Micevic2
1Department of Chemistry, Yale University, New Haven, Connecticut 06520-8107, United States.
ACS Medicinal Chemistry Letters
|May 22, 2020
Summary
Researchers identified novel small molecule inhibitors targeting DNA methyltransferase 3 beta (DNMT3B), a key factor in melanoma growth. Compound 33h demonstrated potent inhibition, offering a promising avenue for cancer therapy development.
Area of Science:
- Medicinal Chemistry
- Oncology
- Biochemistry
Background:
- DNA methyltransferase 3 beta (DNMT3B) is implicated in cancer progression, particularly melanoma.
- Targeting DNMT3B with small molecules presents a potential therapeutic strategy.
Purpose of the Study:
- To identify and develop novel small molecule inhibitors of DNMT3B.
- To evaluate the potency and selectivity of identified inhibitors against DNMT3B.
Main Methods:
- Homology modeling based on DNMT3A crystal structure for virtual screening.
- In vitro fluorogenic and UHPLC-based assays to determine IC50 values.
- Structure-activity relationship analysis and de novo drug design.
Main Results:
- Initial virtual screening identified 5 DNMT3B inhibitors (IC50: 13-72 μM).
- Compound 11 exhibited selectivity, inhibiting DNMT3B (22 μM) without affecting DNMT1.
- Further optimization yielded compound 33h with potent DNMT3B inhibition (IC50: 8.0 μM, confirmed at 4.8 μM).
Conclusions:
- Novel small molecule inhibitors of DNMT3B were successfully identified and optimized.
- Compound 33h represents a potent and selective DNMT3B inhibitor with therapeutic potential for melanoma.
- Structure-activity relationships provide a basis for further drug development against DNMT3B.
